SCHEDULE: Andreessen Horowitz Funds Disclose 4.5% Stake in CAMP4

Sentiment:

Beneficial Ownership Report 14 November 2025 6:23 PM

📋All filings for Camp4 Therapeutics CORP

AH Bio Funds and managing members Marc Andreessen and Benjamin Horowitz report beneficial ownership of 4.5% of CAMP4 THERAPEUTICS CORPORATION common stock.

Summary

AH Bio Fund I, L.P. and AH Equity Partners Bio I, L.L.C. beneficially own 1,579,885 shares, representing 3.4% of CAMP4 THERAPEUTICS CORPORATION's common stock.
AH Bio Fund IV, L.P. and AH Equity Partners Bio IV, L.L.C. beneficially own 545,454 shares, representing 1.2% of CAMP4 THERAPEUTICS CORPORATION's common stock.
Marc L. Andreessen and Benjamin A. Horowitz, as managing members of the general partners, each have shared voting and dispositive power over 2,125,339 shares, representing 4.5% of the common stock.
The total shares outstanding used for calculation is 46,880,185 as of September 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 6, 2025.
The reporting persons expressly disclaim status as a 'group' for purposes of this Schedule 13G.
The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing discloses significant beneficial ownership by Andreessen Horowitz-affiliated funds and principals, which can be viewed as a positive signal of institutional confidence in CAMP4 THERAPEUTICS CORPORATION. However, it is a routine ownership disclosure and does not contain operational or financial performance updates.

Positives

Significant institutional investment from Andreessen Horowitz-affiliated funds and principals, potentially signaling confidence in CAMP4 THERAPEUTICS CORPORATION.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders: Provides transparency regarding significant institutional ownership, potentially influencing market perception and liquidity.

Key Dates

Date	Description
2025-09-30	Date of event requiring the filing of this statement, reflecting the beneficial ownership percentages.
2025-11-06	Date of Issuer's Quarterly Report on Form 10-Q, which reported 46,880,185 shares outstanding.
2025-11-14	Date of filing of this Schedule 13G Amendment No. 1.

Recommendation

hold

This filing is a routine disclosure of beneficial ownership by institutional investors and their principals. While the involvement of prominent investors like Andreessen Horowitz can be seen as a positive signal, the filing itself does not provide new operational, financial, or strategic information about CAMP4 THERAPEUTICS CORPORATION that would warrant a change in investment recommendation. Investors should consider this information in conjunction with the company's financial performance and strategic updates.

Keywords

CAMP4 THERAPEUTICS CORPORATION, 13G, beneficial ownership, Andreessen Horowitz, AH Bio Fund, institutional investment, common stock, biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.